RegulatoryCompany release

Intellia's lonvo-z gene-editing BLA gets Priority Review with March 2027 FDA goal date

🇺🇸 Intellia Therapeutics, Inc. (NTLA) · Thu 05 Nov 2026

Intellia's Q3 2026 update confirms FDA acceptance of its hereditary angioedema CRISPR therapy filing, alongside completed MAGNITUDE-2 enrolment and a new loan of up to $400 million.

Intellia Therapeutics reported its third-quarter 2026 results on 5 November, confirming that the US Food and Drug Administration has accepted its biologics licence application (BLA) for lonvo-z. The product is an in vivo CRISPR-based, one-time therapy for hereditary angioedema (HAE).

The agency granted Priority Review and set a PDUFA action date of 10 March 2027. Priority Review is an FDA designation that shortens the target review timeline for products that may offer significant improvements in the treatment of serious conditions.

In its pipeline update, the company said it has completed enrolment in MAGNITUDE-2, a Phase 3 trial of nex-z in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).

On finances, Intellia reported a cash position of $614.8 million. It also arranged a term loan of up to $400 million with OrbiMed. The company's announcement, as summarised here, did not provide further detail on the loan terms in the material available to VigiEye.

What it means for your team

  • Regulatory teams tracking gene-editing products should note the 10 March 2027 PDUFA date as a fixed milestone for the first in vivo CRISPR therapy filing in HAE.
  • Market-access and payer-engagement planners in HAE may need to begin assessing how a one-time therapy would sit alongside existing chronic treatments, pending the FDA decision.
  • Pharmacovigilance and quality groups should watch for post-approval commitments typical of novel gene-editing products, though none are described in the source.

Company's press release (SEC filing): Intellia Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Intellia Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →